Importance of diagnostics and therapy of COVID neuroinfection urological complications for internal medicine


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Damage of nervous system structures during coronavirus infection is a very diverse process; among the other things, it affects also the genitourinary organs activity. Such kind of disorders can manifest themselves in disturbances of urination - a complex and polyhedral process of emptying the bladder, requiring complex interactions between the autonomic (sympathetic and parasympathetic) and somatic parts of the nervous system. These symptoms should be identified already at the first contact between the doctor and the patient, provided that they are well known and targeted for detection. An important role in the diagnosis of urological disorders (including those as complications of COVID-neuroinfection) plays the study of anamnesis, while we should not forget about the need for an individual approach to diagnosis, taking into account the individual peculiarities of the each patient. Drug therapy should be carried out both by an urologist and neurologist at the stage of therapy and also at the stage of rehabilitation.

Full Text

Restricted Access

About the authors

Vladimir V. Borisov

I.M. Sechenov First Moscow State Medical University (Sechenov University) of the Ministry of Healthcare of Russia

Email: wb56@yandex.ru
MD, professor

References

  1. РИА Новости. Назван симптом у заразившихся «омикроном», вызывающий сильную боль. Обновлено: 09.02.2022. Доступ: https://ria.ru/20220209/simptom-1771795152.html (дата обращения - 10.02.2022)
  2. Вишневский Е.Л., Пушкарь Д.Ю., Лоран О.Б. с соавт. Урофлоуметрия. М.: Печатный город. 2004: 220 с
  3. Andrew J., Nathan P.W. Lesions of the anterior frontal lobes and disturbances of micturition and defecation. Brain. 1964; 87: 233-62. https://dx.doi.org/10.1093/brain/87.2.233.
  4. Griffiths D.J. Use of functional imaging to monitor central control of voiding in humans. In: Andersson K.-E., Michel M.C., editors. Urinary tract, Handbook of experimental pharmacology 202. Springer-Verlag Berlin Heidelberg. 2011; pp. 81-97. ISBN: 978-3-642-16499-6.
  5. Григорашвили И.И. Значение дисфункции вегетативной нервной системы при идиопатическом гиперактивном мочевом пузыре у женщин. Дис. канд. мед. наук. М., 2009
  6. Burkhard F.C., Lucas M.G., Berghmans L.C. et al. EAU guidelines on urinary incontinence in adults. 2016. URL: https://uroweb.org/wp-content/uploads/EAU-Guidelines-Urinary-Incontinence-2016.pdf (date of access - 11.01.2022).
  7. Napier C., Gupta P. Darifenacin is selective for the human recombinant M3 receptor subtype. Neurourol. Neurourol Urodyn. 2002; 21(4): A445.
  8. Doroshyenko O., Jetter A., Odenthal K.P., Fuhr U. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet. 2005; 44(7): 701-20. https://dx.doi.org/10.2165/00003088-200544070-00003.
  9. van de Waterbeemd H., Camenisch G., Folkers G. et al. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target. 1998; 6(2): 151-65. https://dx.doi.org/10.3109/10611869808997889.
  10. Kessler T.M., Bachmann L.M., Minder C. et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One. 2011; 6(2): e16718. https://dx.doi.org/10.1371/journal.pone.0016718.
  11. Abrams P., Cardozo L., Khoury S., Wein A.J.; International Continence Society. Incontinence: 5th International consultation on incontinence, Paris, February 2012. 5th Edition. Paris; ICUD-EAU. 2013; 1956 pp. ISBN: 978-9953-493-21-3.
  12. Staskin D., Kay G., Tannenbaum C. et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder.Int J Clin Pract. 2010; 64(9): 1294-300. https://dx.doi.org/10.1111/j.1742-1241.2010.02433.x.
  13. Pietzko A., Dimpfel W., Schwantes U., Topfmeier P. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol. 1994; 47(4): 337-43. https://dx.doi.org/10.1007/BF00191165.
  14. Diefienbach K., Donath F., Maurer A. et al. Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin Drug Investig. 2003; 23(6): 395-404. https://dx.doi.org/10.2165/00044011-200323060-00003.
  15. Herberg K.W., Fussgen I. Einfluss von trospiumchlorid, oxybutynin-HCl und propiverin-HCl auf sicherheitsrelevante leistungen. Geriatrie Forschung. 1997; 7(2): 77-83. [Article in German].
  16. Rudy D. Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU Int. 2006; 97(3): 540-46. https://dx.doi.org/10.1111/j.1464-410X.2006.06035.x.
  17. Кривобородов Г.Г., Тур Е.И., Ефремов Н.С. Троспия хлорид в лечении гиперактивного мочевого пузыря у пациентов пожилого и старческого возраста с неврологическими заболеваниями (данные многоцентровой наблюдательной программы «РЕСУРС»). Consilium Medicum. 2016; 7: 55-59
  18. Wu Z.S., Zhang Z.Q., Wu S. Focus on the crosstalk between COVID-19 and urogenital systems. J Urol. 2020; 204(1): 7-8. https://dx.doi.org/10.1097/JU.0000000000001068.
  19. Peng L., Liu J., Xu W. et al. SARS-CoV-2 can be detected in urine, blood, anal swabs, and oropharyngeal swabs specimens. J Med Virol. 2020; 92(9): 1676-80. https://dx.doi.org/10.1002/jmv.25936.
  20. Guan W.J., Ni Z.Y., Hu Y. et al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med. 2020; 382(18): 1708-20. https://dx.doi.org/10.1056/NEJMoa2002032.
  21. Sun J., Zhu A., Li H. et al. Isolation of infectious SARS-CoV-2 from urine of a COVID-19 patient. Emerg Microbes Infect. 2020; 9(1): 991-93. https://dx.doi.org/10.1080/22221751.2020.1760144.
  22. Wang W., Xu Y., Gao R. et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020; 323(18): 1843-44. https://dx.doi.org/10.1001/jama.2020.3786

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies